reading satiety threads from 2024 and half of it aged badly
Something I keep coming back to: reading satiety threads from 2024 and half of it aged badly.
Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.
The honest state of the evidence on this board, since somebody should write it down.
Published clinical data exists and is genuinely interesting, particularly in combination. Independent purity data from members is thin — a handful of results across the whole site, against hundreds for the older molecules. Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
What follows practically: buy small if you buy at all, test what you get and post the result, and treat confident rankings against established compounds as the extrapolation they are. The board gets better as the log fills, and right now the log is nearly empty.
Reading the trial literature on this without misleading yourself.
Separate the monotherapy arms from the combination arms before you do anything else. They report different effect sizes and different tolerability, and almost every summary that circulates blends them.
Then read the tolerability tables rather than the headline. In combination work the interesting question is whether adding a second mechanism adds effect without adding proportionate side effects, and that question is answered in a table nobody quotes.
Finally, note the durations. Comparing a shorter readout here with a longer one from an established compound is not a comparison at all.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
phase 3 data will change most of what gets said here
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing.
Agreed, and the combination arms are where the interesting numbers actually live.
nothing here is approved as a standalone product and research material is not for human use
read the combination arms separately from the monotherapy arms
That is preclinical work and the thread is treating it as a human finding.
Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.
independent purity data on this compound is thin
Are you comparing against a GLP-1 monotherapy result? They are not comparable.
Are you comparing against a GLP-1 monotherapy result?
This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
do not assume the dosing intuitions from the GLP-1 boards transfer
Is there any independent purity data on this compound that you have seen?
Standing reminder: nothing here is approved standalone, research material is not for human use, and no dosing schedules for other members.
Yes. Anyone reading this board should hold their conclusions loosely until phase 3 reports.
long-acting amylin is the whole point of the molecule
That result is preclinical. Worth flagging, since the thread has been reading it as human data.
- 1The engineering problem was duration: native amylin is short-acting and…9 comments in this branch · started by u/bpc_sceptic